A major California health insurer is set to offer one of the world’s top-selling drugs for free in a bid to show it can reach Americans affordably
This article is available to Insider Pro subscribers only. Sign in or register to be an Insider Pro and access ALL LOCKED articles.
Social Security 2025: How the Fed’s Interest Rate Decision Affects Next Year’s COLA
STAT+: Pharmalittle: We’re reading about a Blue Cross California deal for Humira, Gilead licensing an HIV drug, and more
Username
Password
Remember Me
Social Security 2025: How the Fed’s Interest Rate Decision Affects Next Year’s COLA
STAT+: Pharmalittle: We’re reading about a Blue Cross California deal for Humira, Gilead licensing an HIV drug, and more
Advisor News
- How OBBBA is a once-in-a-career window
- RICKETTS RECAPS 2025, A YEAR OF DELIVERING WINS FOR NEBRASKANS
- 5 things I wish I knew before leaving my broker-dealer
- Global economic growth will moderate as the labor force shrinks
- Estate planning during the great wealth transfer
More Advisor NewsAnnuity News
- An Application for the Trademark “DYNAMIC RETIREMENT MANAGER” Has Been Filed by Great-West Life & Annuity Insurance Company: Great-West Life & Annuity Insurance Company
- Product understanding will drive the future of insurance
- Prudential launches FlexGuard 2.0 RILA
- Lincoln Financial Introduces First Capital Group ETF Strategy for Fixed Indexed Annuities
- Iowa defends Athene pension risk transfer deal in Lockheed Martin lawsuit
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- An Application for the Trademark “HUMPBACK” Has Been Filed by Hanwha Life Insurance Co., Ltd.: Hanwha Life Insurance Co. Ltd.
- ROUNDS LEADS LEGISLATION TO INCREASE TRANSPARENCY AND ACCOUNTABILITY FOR FINANCIAL REGULATORS
- The 2025-2026 risk agenda for insurers
- Jackson Names Alison Reed Head of Distribution
- Consumer group calls on life insurers to improve flexible premium policy practices
More Life Insurance News